Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 36-month prospective, open-label, multicenter, observational to evaluate quality of life outcomes in patients with relapsing-remitting multiple sclerosis treated with Alemtuzumab in routine clinical practice

Next Previous
X
Search
Trial Profile

A 36-month prospective, open-label, multicenter, observational to evaluate quality of life outcomes in patients with relapsing-remitting multiple sclerosis treated with Alemtuzumab in routine clinical practice

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms LEMQoL

    • Most Recent Events

    • 02 Jul 2019 Trial design (n= 306) of Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting has been presented at the 5th Congress of the European Academy of Neurology
    • 26 Jul 2017 New trial record
    • 27 Jun 2017 Trial design of the study (n=550) presented at the 3rd Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top